Revenue
2022
2023
2024
2025
Xilio Therapeutics, Inc. (XLO)
Price$9.00Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | $0 | $0 | — | — |
| Research & development | $56.0M | $41.2M | $52.1M | $59.2M | $51.2M | $43.9M |
| Operating expenses | $85.7M | $66.9M | $79.1M | $89.1M | $75.0M | $54.6M |
| Operating income | −$42.0M | −$60.6M | −$79.1M | −$89.1M | −$75.0M | −$54.6M |
| Operating margin | −95.92% | −954.95% | — | — | — | — |
| EBITDA | −$40.4M | −$58.9M | −$77.2M | −$87.3M | −$73.5M | −$53.5M |
| EBITDA margin | −92.40% | −929.04% | — | — | — | — |
| Net income | −$35.0M | −$58.2M | −$76.4M | −$88.2M | −$75.8M | −$55.2M |
| Net profit margin | −80.05% | −918.05% | — | — | — | — |
| Basic EPSper basic share | -$4.19 | -$15.24 | -$38.92 | -$45.08 | -$189.28 | -$1,475.88 |
| Diluted EPSper diluted share | -$4.19 | -$15.24 | -$38.92 | -$45.08 | -$189.28 | -$1,475.88 |
Owners
Reported shareholders
10.09%of listed shares
Bain Capital Life Sciences Investors, LLC664.02K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
GILEAD SCIENCES, INC. | —9.11M shares |
GKCC, LLC / Chudnovsky Yekaterina | —7M shares |
Bain Capital Life Sciences Investors, LLC | 10.09%664.02K shares |
ORBIMED ADVISORS LLC | 9.00%592.3K shares |
Frazier Life Sciences Management, L.P. | 6.42%422.51K shares |
Russo Rene | ≈4.95%325.42K shares |
Stonepine Capital Management, LLC | 3.43%225.99K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.71%178.52K shares |
Sio Capital Management, LLC | 2.32%152.46K shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.70%111.54K shares |
Merck & Co., Inc. | 1.61%105.98K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.97%64.15K shares |
MORGAN STANLEY | 0.87%56.95K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.59%39.06K shares |
Luptakova Katarina | ≈0.51%33.25K shares |
CITADEL ADVISORS LLC | 0.39%25.95K shares |
Frankenfield Christopher James | ≈0.38%24.77K shares |
VANGUARD FIDUCIARY TRUST CO | 0.34%22.59K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.27%17.54K shares |
TWO SIGMA INVESTMENTS, LP | 0.22%14.54K shares |
Percentages use 6.58M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 26, 2026Form 4 | Shannon James SamuelDirector | BuyCommon Stock | 5.0K | $8.79 | $43.9K | 10.0K |
| Feb 13, 2026Form 4 | GILEAD SCIENCES, INC.TenPercentOwner | BuyPrefunded Warrants (right to buy) · derivative | 3.74M | $0.53 | $1.98M | 40.38M |
| Jan 2, 2026Form 4 · 10b5-1 | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | SellCommon Stock | 1.8K | $0.64 | $1.2K | 6.4K |
| Jan 2, 2026Form 4 · 10b5-1 | Frankenfield Christopher JamesChief Financial Officer | SellCommon Stock | 7.0K | $0.64 | $4.5K | 24.8K |
| Jun 17, 2025Form 4 | Shannon James SamuelDirector | BuyCommon Stock | 25.0K | $0.69 | $17.3K | 70.0K |